- Home
- IMNN vs TRIB Comparison
IMNN vs TRIB Comparison
Compare IMNN & TRIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- TRIB
- Stock Information
- Founded
- IMNN 1982
- TRIB 1992
- Country
- IMNN United States
- TRIB Ireland
- Employees
- IMNN N/A
- TRIB N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- IMNN Health Care
- TRIB Health Care
- Exchange
- IMNN Nasdaq
- TRIB Nasdaq
- Market Cap
- IMNN 14.3M
- TRIB 15.8M
- IPO Year
- IMNN 1985
- TRIB N/A
- Fundamental
- Price
- IMNN $0.75
- TRIB $1.48
- Analyst Decision
- IMNN Strong Buy
- TRIB
- Analyst Count
- IMNN 2
- TRIB 0
- Target Price
- IMNN $20.50
- TRIB N/A
- AVG Volume (30 Days)
- IMNN 199.0K
- TRIB 166.9K
- Earning Date
- IMNN 11-07-2024
- TRIB 11-15-2024
- Dividend Yield
- IMNN N/A
- TRIB N/A
- EPS Growth
- IMNN N/A
- TRIB N/A
- EPS
- IMNN N/A
- TRIB N/A
- Revenue
- IMNN N/A
- TRIB $58,652,000.00
- Revenue This Year
- IMNN N/A
- TRIB $17.64
- Revenue Next Year
- IMNN N/A
- TRIB $9.84
- P/E Ratio
- IMNN N/A
- TRIB N/A
- Revenue Growth
- IMNN N/A
- TRIB 8.60
- 52 Week Low
- IMNN $0.48
- TRIB $1.05
- 52 Week High
- IMNN $3.65
- TRIB $3.55
- Technical
- Relative Strength Index (RSI)
- IMNN 27.97
- TRIB 42.63
- Support Level
- IMNN $0.71
- TRIB $1.49
- Resistance Level
- IMNN $0.84
- TRIB $1.70
- Average True Range (ATR)
- IMNN 0.07
- TRIB 0.16
- MACD
- IMNN -0.02
- TRIB -0.03
- Stochastic Oscillator
- IMNN 11.00
- TRIB 5.56
About IMNN Imunon Inc.
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.
About TRIB Trinity Biotech plc
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.